One of the current most effective CAR T cell therapies targets CD19, an antigen expressed by B cells in all stages of development until differentiation in plasmocytes, including B cell malignancies, such as Hodgkin (HL) and non-Hodgkin lymphoma (NHL), acute (ALL) or chronic lymphocytic leukemia (CLL) [4]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.